Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection

NCT02185794 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02185794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2014
Completion date
September 28, 2015
Enrollment
101 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection